MedTrace Logo

Added Value of Gadoxetic Acid-enhanced Liver MRI

NCT03045419 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2017-02-07

No results posted yet for this study

Summary

It would be valuable to evaluate whether gadoxetic acid-enhanced liver MRI would provide additional value for characterizing atypical or small (1\~2cm) hepatic nodules at CT and to reduce the necessity of biopsy in patients with high risk of HCC.

Therefore, the purpose of this study is to evaluate added value of gadoxetic acid-enhanced MRI for diagnosis of HCC in patients with small (10-19mm) or atypical hepatic nodules at CT.

Conditions

  • Hcc
  • Diagnosis

Interventions

PROCEDURE

gadoxetic acid-enhanced liver MRI

liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jeong Min Lee, MD · Seoul National University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-29
Primary Completion
2013-11-24
Completion
2016-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03045419 on ClinicalTrials.gov